Results 161 to 167 of about 16,400 (167)

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Blood, 2013
Marcel Spaargaren, Spaargaren Marcel, Chang Betty Y   +2 more
exaly  

Management of adverse effects/toxicity of ibrutinib

Critical Reviews in Oncology/Hematology, 2019
Semra PAYDAŞ
exaly  

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

Proceedings of the National Academy of Sciences of the United States of America, 2015
Idit Sagiv-Barfi, Ronald Levy, Debra K Czerwinski   +2 more
exaly  

Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

British Journal of Haematology, 2018
Shaojun Zhang, Rashmi Kanagal-Shamanna, Linghua Wang   +2 more
exaly  

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

Annals of Oncology, 2015
Dai Chihara, Richard Champlin, John Seymour   +2 more
exaly  

Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants

Pharmacology Research and Perspectives, 2015
exaly  

Stable isotope‐labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults

British Journal of Clinical Pharmacology, 2016
exaly